Encephalopathy syndrome in children with hemato-oncological disorders is not always posterior and reversible.
BACKGROUND
Posterior reversible leukoencephalopathy (PRES) is a clinical-radiological event that can affect children undergoing chemotherapy regimen. Studies have shown that it is not always reversible, in spite of its original definition. We analyzed PRES cases which occurred during the last 10 years at our institute to focus on their clinical, radiological and EEG follow-up.


METHODS
We analyzed 12 cases of PRES in children who underwent intensive chemotherapy regimens, detailing the acute neurological presentation of the syndrome, their neuro-imaging characteristics (MRI) and EEG findings, in both an acute phase and during follow-up.


RESULTS
All patients survived the acute event, showing a clinical recovery of the acute neurological signs in 1-3 days and normalization of the EEG pattern in a period ranging from 1 to 8 months. During long term follow-up, four patients developed either clinical impairment or EEG-MRI anomalies.


CONCLUSIONS
We suggest that a long term follow-up is necessary to determine the reversibility of the neurological events. Clinical observation, as well as EEG and MRI should be included in follow-up evaluations.
Lucchini
Giovanna
G
Pediatric Department, University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy. giovanna.lucchini@pediatriamonza.it
Grioni
Daniele
D
Colombini
Antonella
A
Contri
Margherita
M
De Grandi
Carlo
C
Rovelli
Attilio
A
Conter
Valentino
V
Masera
Giuseppe
G
Jankovic
Momcilo
M
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001927:Brain Diseases / Q000150:complications* / Q000473:pathology* / Q000503:physiopathology*; D002648:Child; D002675:Child, Preschool; D038524:Diffusion Magnetic Resonance Imaging; D004569:Electroencephalography; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D013577:Syndrome
D000970:Antineoplastic Agents